Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Tarsus Pharmaceuticals Inc TARS

Healthcare
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API... see more

Recent & Breaking News (NDAQ:TARS)

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

GlobeNewswire August 11, 2022

Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

GlobeNewswire August 5, 2022

Certara Appoints Rosemary Crane as New Independent Board Member

GlobeNewswire July 25, 2022

Tarsus to Present at the Jefferies 2022 Healthcare Conference

GlobeNewswire May 27, 2022

Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

GlobeNewswire May 10, 2022

Tarsus to Present at Bank of America 2022 Healthcare Conference

GlobeNewswire May 6, 2022

Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

GlobeNewswire May 5, 2022

Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

GlobeNewswire May 3, 2022

Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

GlobeNewswire May 2, 2022

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year

GlobeNewswire May 2, 2022

Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

GlobeNewswire April 29, 2022

Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting

GlobeNewswire April 26, 2022

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements

GlobeNewswire March 14, 2022

Tarsus to Present at Upcoming Investor Conferences

GlobeNewswire March 9, 2022

Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire February 3, 2022

Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03

GlobeNewswire February 2, 2022

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility

GlobeNewswire February 2, 2022

Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors

GlobeNewswire January 4, 2022

Tarsus to Participate at Upcoming Virtual Investor Conferences

GlobeNewswire November 23, 2021

Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

GlobeNewswire November 10, 2021